long term effects of glp 1 agonists Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus GLP-1 Medications: Everything You Need

Trials to date have focused on weight and metabolic outcomes, with lean mass reduction typically reported as a secondary endpoint and without standardized functional measures

This is a meaningful advantage over some injectable GLP-1 agonists, particularly exenatide, which is renally cleared and contraindicated in severe renal impairment

If additional glycemic control is needed, the dose can be increased in 2.5-mg increments every 4 weeks to a maximum of 15 mg once weekly

However, it had gastrointestinal side effects, with 46% of subjects experiencing nausea and 13% experiencing vomiting

Studies on T2R gene expression in the human pancreas confirmed the presence of multiple TAS2R receptors